Hunan Warrant Pharmaceutical (688799.SH) achieved a net profit of 172 million yuan in 2024, a year-on-year decrease of 18.43%.

Hunan Warrant Pharmaceutical (688799.SH) disclosed its preliminary financial results for the year 2024, reporting an operating income of 1.413 billion yuan, a decrease of 1.38% year-on-year. The net profit attributable to the owners of the parent company was 172 million yuan, a decrease of 18.43% year-on-year. The basic earnings per share were 1.84 yuan. During the reporting period, the slight decrease in operating income was mainly due to a decrease in sales revenue caused by a decline in market selling prices of the company's main formulated products. The decrease in net profit attributable to the owners of the parent company was mainly due to a significant increase in research and development expenses compared to the previous year.